Abstract P060 – Table 1. Baseline characteristics of the study population
| DTG regimes N = 20 | NODTG regimes N = 23 | p value | |
|---|---|---|---|
| Sex Male, n (%) | 17 (85.0) | 19 (82.6) | 0.832 |
| Median age, years [IQR] | 33.5 [28 to 42] | 45 [40 to 53] | 0.006 |
| Risk, n (%) Heterosexual | 4 (20.0) | 8 (34.8) | 0.281 |
| Risk, n (%) MSM | 16 (80.0) | 15 (65.2) | |
| Country of origin, n (%) Italy | 17 (85.0) | 18 (78.3) | 0.573 |
| Country of origin, n (%) Romania | 2 (10.0) | 2 (8.7) | |
| Country of origin, n (%) Africa | 0 (0.0) | 1 (4.4) | |
| Country of origin, n (%) Norway | 1 (5.0) | 0 (0.0) | |
| Country of origin, n (%) Portugal | 0 (0.0) | 1 (4.4) | |
| Country of origin, n (%) Peru | 0 (0.0) | 1 (4.4) | |
| Reason for HIV test, n (%) Risk perception | 8 (40.0) | 6 (26.1) | 0.441 |
| Reason for HIV test, n (%) Flu‐like syndrome | 6 (30.0) | 6 (26.1) | |
| Reason for HIV test, n (%) Positive partner | 3 (15.0) | 2 (8.7) | |
| Reason for HIV test, n (%) Blood donation | 0 (0.0) | 1 (4.4) | |
| Reason for HIV test, n (%) Screening for other diseases | 0 (0.0) | 3 (13.0) | |
| Reason for HIV test, n (%) Unknown | 3 (15.0) | 5 (21.7) | |
| HCV Ab positive, n (%) | 1 (5.0) | 0 (0.0) | 0.278 |
| HBsAg positive, n (%) Negative | 19 (95.0) | 14 (60.9) | 0.028 |
| HBsAg positive, n (%) Positive | 1 (5.0) | 6 (26.1) | |
| HBsAg positive, n (%) Unknown | 0 (0.0) | 3 (13.0) | |
| Resistance at baseline, n (%) Negative | 14 (60.0) | 23 (100) | 0.005 |
| Resistance at baseline, n (%) NRTI | 2 (10.0) | 0 (0.0) | |
| Resistance at baseline, n (%) NNRTI | 2 (10.0) | 0 (0.0) | |
| Resistance at baseline, n (%) NRTI+NNRTI | 1 (5.0) | 0 (0.0) | |
| Resistance at baseline, n (%) PI | 1 (5.0) | 0 (0.0) | |
| Median CD4 diagnosis cells/µL [IQR] | 504 [311 to 710] | 557 [339 to 717] | 0.792 |
| Median HIV‐RNA Log 10 copies/mL [IQR] | 6.0 [5.4 to 6.4] | 5.5 [4.9 to 6.3] | 0.173 |
| Median days from diagnosis to start therapy [IQR] | 10 [5 to 18] | 22 [4 to 28] | 0.387 |
| Median time to achieve <50 copies/mL (day) | 103 [58 to 190] | 121 [60 to 197] | 0.903 |
| Number of drugs 2 | 1 (5.0) | 0 (0.0) | 0.554 |
| Number of drugs 3 | 15 (75.0) | 18 (78.3) | |
| Number of drugs 4 | 4 (20.0) | 5 (21.7) | |
| Single tablet regimen, n (%) | 6 (30.0) | 11 (47.8) | 0.233 |
| Fever >38°, n (%) | 10 (50.0) | 9 (39.1) | 0.430 |
| Lymphoadenopathy, n (%) | 10 (50.0) | 12 (52.2) | 0.887 |
| GI symptoms (diarrhoea/vomit), n (%) | 5 (25.0) | 2 (8.7) | 0.149 |
| CD4 < 350 cells/mm3 at diagnosis, n (%) | 6 (30) | 6 (26.1) | 0.081 |
| Lue serology positive at the diagnosis, n (%) | 3 (15.0) | 3 (13.0) | 0.853 |